Vera Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Vera Therapeutics (NASDAQ: VERA), a late clinical-stage biotechnology company focused on immunological disease treatments, has announced its participation in two upcoming investor conferences in New York.

The company will participate in the Cantor Global Healthcare Conference on September 4, 2025, at 9:10am ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 5:35pm ET. Both events will feature fireside chats and one-on-one meetings with management.

A webcast replay will be accessible for 90 days through the company's website.

BRISBANE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.

Investor Conference Details:

• Cantor Global Healthcare Conference
  Format: Fireside Chat and 1x1s
  Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=61704087&checkCompany=1&checkEmail=1&checkName=1 
  Date: Thursday, September 4, 2025
  Time: 9:10am ET
  Location: New York, NY

• Morgan Stanley 23^rd Annual Global Healthcare Conference
  Format: Fireside Chat and 1x1s
  Date: Monday, September 8, 2025
  Time: 5:35pm ET
  Location: New York, NY

A replay of the webcast will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.

About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.

Forward-Looking Statements

This press release and the upcoming presentations may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Such forward-looking statements include statements regarding, among other things, commitments, aspirations and goals related to Vera’s drug candidates, and the date and time of upcoming presentations. Because such statements are subject to risk and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believe,” “plan,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera’s business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

When is Vera Therapeutics (VERA) presenting at the Cantor Global Healthcare Conference 2025?

Vera Therapeutics will present at the Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 9:10am ET in New York, NY.

When is Vera Therapeutics (VERA) presenting at the Morgan Stanley Healthcare Conference 2025?

Vera Therapeutics will present at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2025, at 5:35pm ET in New York, NY.

How can I access Vera Therapeutics (VERA) conference presentations?

The presentations can be accessed through a webcast, with replays available for 90 days in the 'Investor Calendar' section of Vera Therapeutics' website.

What type of company is Vera Therapeutics (VERA)?

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases.